Various Cancer and Hematology Centers of Western Michigan (CHCWM) and START Midwest clinical trials were presented last weekend as a part of the American Society of Clinical Oncology (ASCO)’s Virtual Annual Meeting. ASCO is a platform for scientists and clinicians to share knowledge gained from conducting clinical oncology research. CHC would like to congratulate the CHCWM Research and START Midwest teams for their accomplishments. Check out the trial abstracts and principal investigators featured below:
- “First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.”
- “Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated Results from the phase III CASPIAN study.”
- Yuanbin Chen, MD, PhD
- “Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.”
- Yuanbin Chen, MD, PhD
- “Molecular diagnostic testing patterns in patients (pts) with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in the Connect MDS/AML Registry.”
- Timothy O’Rourke, MD (formerly)
- Erin Pettijohn, MD
- “Factors influencing first-line therapy of acute myeloid leukemia (AML) patients (pts) in the Connect MDS/AML Disease Registry.”
- Timothy O’Rourke, MD (formerly)
- Erin Pettijohn, MD
- “Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the CONNECT MDS/AML disease registry.”
- Timothy O’Rourke (formerly)
- Erin Pettijohn, MD
- “Connect MDS and AML: The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry.”
- Timothy O’Rourke (formerly)
- Erin Pettijohn, MD
- “A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer.”
- “Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers.”
- “PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC).”
- “PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).”
- “RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.”
- Yuanbin Chen, MD, PhD
- “RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.”
- Yuanbin Chen, MD, PhD
- “Incidence of solid tumors or lymphoma in patients with polycythemia vera: Data from the REVEAL study.”
- “Self-reported quality-of-life (QoL) impairment and productivity loss in patients with polycythemia vera (PV) enrolled in the REVEAL study.”
- Brett Brinker, MD, MS
- “Disease, clinical, and treatment characteristics of patients (pts) with polycythemia vera (PV) enrolled in the REVEAL study.”
- Brett Brinker, MD, MS
- “Predictors of performing response monitoring in patients with chronic-phase chronic myeloid leukemia (CP-CML) in a prospective observational study (SIMPLICITY).”
- Timothy O’Rourke, MD
- “Cytogenetic and molecular testing in patients with chronic myeloid leukemia (CML) in a prospective observational study (SIMPLICITY).”
- Timothy O’Rourke, MD
- Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors. (Poster Discussion)
- Nehal Lakhani, MD, PhD
- First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in U.S. patients with metastatic solid tumors. (Poster Discussion)
- Nehal Lakhani, MD, PhD
- CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer. (Oral Presentation)
- Nehal Lakhani, MD, PhD
- AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors. (Poster Discussion)
- Nehal Lakhani, MD, PhD
- Sreenivasa Chandana, MD, PhD
- Manish Sharma, MD
- A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.
- Nehal Lakhani, MD, PhD
- Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors. (Poster Discussion)
- Manish Sharma, MD
- First-in-human phase I study of SY-5609, an oral, potent, and selective noncovalent CDK7 inhibitor, in adult patients with select advanced solid tumors. (Poster Discussion)
- Manish Sharma, MD